Biotech Lock Up Expiration Hell Portfolio: Wave II Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock Up Expiration Hell Portfolio: Wave II

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (2)	3/26/2004 11:41:48 AM
From: keokalani'nui	Read Replies (1) of 107

Reuters Anadys Pharmaceuticals IPO priced below range at $7 Thursday March 25, 8:09 pm ET NEW YORK, March 25 (Reuters) - Biopharmaceutical company Anadys Pharmaceuticals Inc., which is developing hepatitis C treatments, priced its initial public offering at $7 per share, the underwriters said on Thursday. The San Diego, California-based company had previously estimated the IPO of 6.25 million shares would sell for $11-$13 per share. The underwriters, led by SG Cowen and Piper Jaffray, will have the option of buying 937,500 more shares in the event of heavy demand. The company, which also focuses on treatments for bacterial infections, has applied to list its shares on Nasdaq under the symbol "ANDS" (Nasdaq:ANDS - News).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next